Protect Pharmaceutical Corporation (PRTT)
USD 1.02
(2.0%)
USD 1.02
(2.0%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | 4.04 Million | -67.19 Million | 10.5 Million | 6.77 Million | 11.97 Thousand | -36.08 Thousand |
| Net Income | 45.91 Million | 22.44 Million | 20.2 Million | 5.81 Million | -1873.00 | -3726.00 |
| Depreciation & Amortization | - | - | - | - | - | - |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | - | - | - | - | - | - |
| Change in working capital | -41.87 Million | -91.54 Million | -9.7 Million | 961.19 Thousand | 13.84 Thousand | 24.7 Thousand |
| Other non-cash items | 15.13 Million | 54.41 Million | 2.34 Million | - | - | -57.06 Thousand |
| Investing Cash Flow | 12.87 Million | 46.06 Million | 17.63 Million | -19.8 Million | -140.5 Thousand | - |
| Investments in PPE | -4.04 Million | -1.81 Million | -75.4 Million | -19.8 Million | - | - |
| Acquisitions | 7.51 Million | 23.92 Million | - | - | - | - |
| Investment purchases | - | - | -12.32 Million | - | -140.5 Thousand | - |
| Sales/Maturities of investments | 5.01 Million | - | - | - | - | - |
| Other Investing Activities | 345 Thousand | 23.95 Million | 105.35 Million | - | - | - |
| Financing Cash Flow | 1.6 Million | -9.66 Million | -5.05 Million | 13.1 Million | 143.89 Thousand | 16.1 Thousand |
| Debt repayment | -1.13 Million | -9.66 Million | -5.05 Million | -13.1 Million | - | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | 467 Thousand | - | - | - | 143.89 Thousand | 16.1 Thousand |
| Other Financing Activities | - | - | - | - | - | - |
| Accounts receivables | -16.14 Million | -23.25 Million | 10.25 Million | - | - | - |
| Accounts payables | 1.12 Million | 2.55 Million | -205 Thousand | - | - | - |
| Inventory | -120 Thousand | -31.82 Million | -12.38 Million | - | - | - |
| Other working capital | -26.73 Million | -39.02 Million | -7.36 Million | 961.19 Thousand | 13.84 Thousand | 24.7 Thousand |
| Cash at beginning of period | 1.2 Million | 39.89 Million | 74.49 Thousand | 253.00 | 91.00 | 20.07 Thousand |
| Cash at end of period | 18.21 Million | 1.2 Million | 39.89 Million | 74.49 Thousand | 253.00 | 91.00 |
| Capital Expenditure | -4.04 Million | -1.81 Million | -75.4 Million | -19.8 Million | - | - |
| Effect of forex changes on cash | - | - | 16.73 Million | - | - | - |
| Net cash flow / Change in cash | 17.01 Million | -38.69 Million | 39.82 Million | 74.23 Thousand | 162.00 | -19.98 Thousand |
| Free Cash Flow | - | -69.01 Million | -64.89 Million | -13.02 Million | 11.97 Thousand | -36.08 Thousand |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 FY | 2023 Q4 | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | 13.47 Million | 6.7 Million | 45.91 Million | 14.16 Million | 23.19 Million | 647 Thousand |
| Depreciation & Amortization | - | - | - | - | - | - |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | - | - | - | - | - | - |
| Change in working capital | -10.89 Million | -2.41 Million | -41.87 Million | -37.39 Million | 6.96 Million | -4.02 Million |
| Other non-cash items | 5.93 Million | -1.75 Million | 15.13 Million | 14.66 Million | -621 Thousand | 835 Thousand |
| Investing Cash Flow | - | -9.03 Million | 12.87 Million | - | 9.03 Million | - |
| Investments in PPE | - | -2.36 Million | - | - | - | - |
| Acquisitions | - | - | 7.51 Million | - | 2.01 Million | - |
| Investment purchases | - | -6.67 Million | - | - | 1.65 Million | - |
| Sales/Maturities of investments | - | - | 5.01 Million | - | 5.01 Million | - |
| Other Investing Activities | - | - | 345 Thousand | - | 345 Thousand | - |
| Financing Cash Flow | -303 Thousand | 372 Thousand | 1.6 Million | 467 Thousand | 875 Thousand | - |
| Debt repayment | -303 Thousand | -372 Thousand | -1.13 Million | - | -875 Thousand | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | - | - | 467 Thousand | 467 Thousand | - | - |
| Other Financing Activities | - | - | - | - | - | - |
| Accounts receivables | -5.09 Million | - | -16.14 Million | -14.66 Million | 502 Thousand | -530 Thousand |
| Accounts payables | -837 Thousand | 1.63 Million | 1.12 Million | - | 239 Thousand | -305 Thousand |
| Inventory | - | 120 Thousand | -120 Thousand | - | -120 Thousand | - |
| Other working capital | -4.96 Million | -4.17 Million | -26.73 Million | -22.73 Million | 6.34 Million | -3.19 Million |
| Cash at beginning of period | 13.84 Million | 18.21 Million | 1.2 Million | 42.48 Million | 2.42 Million | 5.8 Million |
| Cash at end of period | 11.9 Million | 13.84 Million | 18.21 Million | 18.21 Million | 42.48 Million | 2.42 Million |
| Capital Expenditure | - | -2.36 Million | - | - | - | - |
| Effect of forex changes on cash | - | - | - | - | - | - |
| Net cash flow / Change in cash | -1.94 Million | -4.37 Million | 17.01 Million | -24.26 Million | 40.05 Million | -3.37 Million |
| Free Cash Flow | 2.58 Million | 1.92 Million | 4.04 Million | -23.23 Million | 30.15 Million | -3.37 Million |
603500
ARQQW
600955
BM
BHM
BRT